drugset / Trial / NCT03702738
Adjunctive NAC in Adult Patients With Pulmonary Tuberculosis
Phase 2
Completed
110 enrolled
The Aurum Institute NPC
National Institute for Medical Research, Tanzania · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
To determine if adjunctive N-acetylcysteine 1200 mg twice a day (BID) accelerates sputum culture conversion and normalization of cellular glutathione in tuberculosis (TB), and to assess its potential effects on lung and immune function
Timeline
- Start
- 2019-03-01
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | N-acetylcysteine | Small molecule | 1200 mg | Oral |